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Abstract
Mild-to-moderate tobacco smoking is highly prevalent in HIV-infected individuals, and is
known to exacerbate HIV pathogenesis. The objective of this study was to determine the
specific effects of mild-to-moderate smoking on viral load, cytokine production, and oxida-
tive stress and cytochrome P450 (CYP) pathways in HIV-infected individuals who have not
yet received antiretroviral therapy (ART). Thirty-two human subjects were recruited and as-
signed to four different cohorts as follows: a) HIV negative non-smokers, b) HIV positive
non-smokers, c) HIV negative mild-to-moderate smokers, and d) HIV positive mild-to-
moderate smokers. Patients were recruited in Cameroon, Africa using strict selection crite-
ria to exclude patients not yet eligible for ART and not receiving conventional or traditional
medications. Those with active tuberculosis, hepatitis B or with a history of substance
abuse were also excluded. Our results showed an increase in the viral load in the plasma of
HIV positive patients who were mild-to-moderate smokers compared to individuals who did
not smoke. Furthermore, although we did not observe significant changes in the levels of
most pro-inflammatory cytokines, the cytokine IL-8 and MCP-1 showed a significant de-
crease in the plasma of HIV-infected patients and smokers compared with HIV negative
non-smokers. Importantly, HIV-infected individuals and smokers showed a significant in-
crease in oxidative stress compared with HIV negative non-smoker subjects in both plasma
and monocytes. To examine the possible pathways involved in increased oxidative stress
and viral load, we determined the mRNA levels of several antioxidant and cytochrome
P450 enzymes in monocytes. The results showed that the levels of most antioxidants are
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unaltered, suggesting their inability to counter oxidative stress. While CYP2A6 was induced
in smokers, CYP3A4 was induced in HIV and HIV positive smokers compared with HIV
negative non-smokers. Overall, the findings suggest a possible association of oxidative
stress and perhaps CYP pathway with smoking-mediated increased viral load in HIV
positive individuals.
Introduction
The prevalence of mild-to-moderate tobacco smoking is approximately 3-fold higher in
HIV-infected individuals (~60%) than in the general population (~ 20%) [1]. Smoking/
nicotine has shown to enhance HIV-1 replication, especially in alveolar macrophages and
microglia [2,3]. The alveolar macrophages obtained from smokers showed higher HIV p24
antigen levels following in vitro infection of HIV than those macrophages obtained from
non-smokers [2]. Similarly, the pretreatment of HIV-infected microglial cells with nicotine
increased HIV-1 expression in a concentration-dependent manner [4]. However, the specific
effects of mild-to-moderate smoking on the components of HIV pathogenesis such as inflam-
matory cytokines and oxidative stress, is poorly studied.
Cytokines/chemokines play a crucial role in HIV pathogenesis by regulating HIV repli-
cation and immune responses [5,6]. Several studies have shown that cytokine dysregulation
contributes to HIV disease progression [7,8]. For example, cytokines have shown to play
an important role in development of viral latency and maintenance of latently infected
CD4+ T cells during antiretroviral therapy (ART) [8]. Furthermore, the myriad of pro-
inflammatory cytokines including tumor necrosis factor (TNF-α), interleukin-2 (IL-2),
and IL-18, present in the plasma and lymphoid tissues, induce HIV replication even after
prolonged ART. Similarly, oxidative stress is known to play a significant role in HIV-1
pathogenesis [9–11]. More specifically, oxidative stress has been linked to HIV-1 replica-
tion in monocytes/macrophages [9,12]. In addition, a report suggested the role of iron and
oxidative stress in smoking-mediated HIV replication in alveolar macrophages [13]. Of im-
portance, the pathway leading oxidative stress, especially in monocytes, in HIV-infected
smokers is unknown.
The nicotine present in tobacco is predominantly metabolized by hepatic cytochrome P450
2A6 (CYP2A6) and lung specific CYP2A13 [14,15]. In smokers resulting reactive metabolites
and oxidative stress, lead to cell toxicity, organ damage, and hepatic and pulmonary carcino-
mas [16,17]. Furthermore, our recent in vitro studies have also shown that acute nicotine
exposure causes increased production of reactive oxygen species (ROS) through CYP2A6-
mediated pathway in monocytic and astrocytic cell lines [18–20]. CYP3A4 metabolizes ap-
proximately 50% of commercially available drugs including ART in the liver [21] resulting in
the production of ROS [22,23]. However, the functional role of CYP3A4 is unknown in mono-
cytes, which is an important site of viral infection and major viral reservoir. Our previous
studies have demonstrated predominant expression of CYP2A6 and CYP3A4 in monocytic
cell lines [24]. In the current study, we sought to determine whether smoking increases viral
replication in clinical samples of HIV-infected smokers. Furthermore, we sought to determine
whether there is a relationship between viral load, cytokines/chemokines, oxidative stress, and
CYP pathways in HIV-infected smokers.
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Materials and Methods
Study Population
Thirty two human subjects were recruited and assigned to four different cohorts as follows: a)
healthy HIV negative control subjects who reported that they were non-smokers (HIV
negative non-smokers), b) HIV positive non-smokers, c) HIV negative mild-to-moderate
smokers, and d) HIV positive mild-to-moderate smokers. Participants were recruited in
Cameroon, Africa, from within a long standing reference population of more than 2000
known HIV positive subjects. The participants provided their written informed consent to
participate in this study. The signed consent form from the participants was stored as hard
copy as well as electronically on a password protected computer. The consent procedure was
approved by Institutional Review Board (IRB) from the University of Missouri-Kansas City,
Kansas City, MO and IRB/Institutional Ethic Committee (IEC) from the Provincial Regional
Hospital, Ministry of Public Health, Bamenda, Cameroon. We performed power analysis
using “Power and Precision” software by considering the magnitude of the known effects of
smoking on HIV replication [4,13] and oxidative stress [18,19]. The results showed that 6–8
samples from each group would provide a power of0.80. Participants between the ages of
21–65 years were recruited, because individuals<13 years and>65 years of age generally
have altered expression of metabolic (CYP) and to some extent antioxidant enzymes (AOEs)
[25, 26]. For those individuals in the HIV negative non-smoker category, we recruited indi-
viduals who reported no history of “cough” and physical examination although some may
have had malaria in the past (Plasmodium falciparum is indigenous in Cameroon). With re-
spect to the HIV negative and positive smokers, mild-to-moderate smokers with a smoking
history of20 pack years (a pack year is defined as smoking at least one pack a day for one
year), were enrolled in the study. The documentation of smoking was determined by a HIV
counselor and the phlebotomist following a personal interview. With respect to the HIV posi-
tive category, individuals with CD4+ counts<600 cells/μl were enrolled. Participants were re-
cruited using the following strict exclusion criteria: 1) Pregnant or lactating women were
excluded since they show increased metabolism of nicotine and cotinine [27] (smoking is rare
among Cameroonian women); 2). Liver damage and lung disease since these alter the metab-
olism of tobacco constituents such as nicotine; 3) Individuals with other infectious diseases,
such as documented malaria, tuberculosis, and hepatitis B since hepatitis and active TB are
prevalent in HIV-infected population, and some of these diseases are known to interact with
HIV [28]; 4) Individuals who were receiving ART. ART drugs or other medications are ex-
pected to interfere with tobacco constituents [16,29]. Sufficient numbers of HIV-infected in-
dividuals who were not already receiving ART or other medication were available among
village populations in Cameroon, because medications or access to CD4 counting is frequent-
ly not available in these areas (WHO, Cameroon 2004–2005 report http://www.who.int/hiv/
HIVCP_CMR.pdf). In order to qualify for free therapy provided by the Cameroonian Gov-
ernment, an adult must obtain a CD4 count and that result must be under 350cells/μl. The
test to determine CD4 count is costly and not available in rural areas. Second, the local recom-
mendation during the period of the study was to initiate therapy when the CD4 count was
<350 cell/μl. 5) Individuals who consume other recreational substances of abuse, e.g. meth-
amphetamine, cocaine, or marijuana. These drugs are expected to interfere with HIV patho-
genesis and/or oxidative stress [30, 31]. Applying these inclusion and exclusion criteria was
challenging but subjects were recruited upon personal interview, analysis of their history, and
following clinical screening for HIV, malaria, and hepatitis B. The clinical screening tests for
malaria and hepatitis were conducted using standard procedures as described [32] and pa-
tients with “cough” suggestive of TB received an AFB or were excluded.
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Determination of CD4 count and viral load
Whole blood was drawn in EDTA tubes from each subject who qualified for the study followed
by confirmation of HIV status and a CD4 count by flow cytometry (Becton Dickenson, San Jose,
CA). The viral load of HIV-infected individuals was determined in plasma using quantitative re-
verse transcriptase polymerase chain reaction (RTPCR) (Roche Amplicor System, Biocentric) at
Pasteur Institute, Yaounde, Cameroon. The remaining sample of plasma from each patient was
frozen immediately and shipped on dry ice to the University of Missouri-Kansas City for analy-
sis of cytokines and determination of markers of oxidative stress and CYP enzymes.
Preparation of peripheral blood mononuclear cells and monocytes
For the peripheral blood mononuclear cells (PBMC) isolation, gradient centrifugation tech-
nique was employed using ficoll hypaque plus. From the PBMCs, monocytes were isolated
using dynabeads flowcomp human CD14 kit (Invitrogen, Grand Island, New York). The
monocytes were immediately lysed using RLT buffer provided in the All prep DNA/RNA/
Protein kit (Qiagen, Valencia, CA). The lysed samples were frozen and shipped to the Universi-
ty of Missouri-Kansas City for further studies.
Cigarette smoke condensate (CSC) treatment and HIV replication in
primary macrophages
Primary monocytes were differentiated into macrophages and infected with HIV-1, prior to
treatment with CSC (Murty Pharmaceuticals, KY), using previously reported protocol [33, 34].
Briefly, PBMCs were plated in T-75 flask and non-adherent cells were removed after 1 h at
37°C. Cells were cultured for 6–8 days in media containing human mCSF to facilitate macro-
phage differentiation. Mature macrophages were collected and activated by treating with poly-
brene (2 μg/ml) for 30 min before HIV infection. Macrophages were infected with TCID50 of
HIV-1 for 2 h and cultured in 6-well plates (1 million/well) for 6 days. Cell supernatant was
collected on days 0, 3, and 6 to analyze p24 levels. Starting day 7, HIV-infected macrophages
were treated, once daily, with 25 ug/ml CSC or equivalent amount of DMSO. During the treat-
ment period, one-half milliliters of fresh media was added daily to each well to avoid cytotoxic-
ity. Supernatant collected on day 11 (24 h after last treatment) was analyzed for viral load using
the HIV type 1 p24 antigen ELISA (ZeptoMetrix, NY).
Multiplex cytokine assay
The protein levels of various pro-inflammatory cytokines/chemokines; RANTES, IL-6, IL-8,
monocyte chemotactic protein-1 (MCP-1), IL1-β, and TNF-α were measured using multiplex
cytokine assay kit (Bio-Rad, CA, USA) as per the manufacturer’s protocol. Briefly, plasma sam-
ples were centrifuged at 3000 g for 10 min and the supernatants were diluted with three vol-
umes of sample diluent. Next, 50 μl of each sample and standards were mixed with magnetic
beads and incubated on a shaker at room temperature for 30 min. The beads were washed and
25 μl of detection antibody was added to each well followed by incubation for 30 min at room
temperature. Furthermore, the samples were washed and incubated with 50 μl streptavidin-PE
conjugate for 10 min. Finally, 125 μl of the assay buffer was added and the samples were ana-
lyzed using Biorad Bioplex HTS (Bio-Rad, CA, USA). The concentrations of the cytokines were
determined with Bio-plex manager 5 using 5-PL statistics using standard curve.
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Quantitation of 8-Hydroxy-20-deoxyguanosine content
The concentration of 8-Hydroxy-20-deoxyguanosine (8-OHdG) was determined in the plasma
samples using oxiselect oxidative DNA damage ELISA kit (Cell Biolabs, San Diego, CA) ac-
cording to manufacturer’s instructions. Briefly, after diluting the plasma 50:50, the samples
along with the 8-OHdG standards provided in the kit were added to an 8-OHdG/BSA conju-
gate on a preabsorbed EIA plate. After incubation for an hour, an anti-8-OHdG primary anti-
body was added, followed by an HRP conjugated secondary antibody. After incubation with
substrate solution for an hour, the reaction was terminated using the assay “stop solution” and
the absorbance was measured at 450 nm using a plate spectrophotometer. The 8-OHdG con-
tent of the DNA in monocytes was estimated using EpiQuik 8-OHdG DNA Damage Quantifi-
cation Direct Kit (Fluorometric) (Epigentek, Farmingdale, NY) following manufacturer’s
instructions. It is a highly sensitive fluorometric technique to detect 8-OHdG by using as low
as 300 ng of unmodified DNA. Initially, DNA is bound to the wells that have a high DNA bind-
ing affinity. Then the 8-OHdG present in the samples is detected by using capture and detec-
tion antibodies. The enhancer solution is used to enhance the signal followed by quantification
by reading the plate in a fluorescence microplate reader equipped with an excitation filter of
530 nm and emission filter of 590 nm. The amount of 8-OHdG in each sample is calculated by
using a standard curve generated from a series of standards.
DNA/RNA/Protein Isolation
Isolation of DNA, RNA, and protein was done from the lysed samples using the All prep
DNA/RNA/Protein QIAGEN Kit (Valencia, CA) by following the manufacturer’s instructions.
Briefly, the lysed sample was homogenized and transferred to the DNA column and the flow
through was transferred to RNA column for obtaining RNA. The flow through from RNA col-
umn was used to precipitate protein using APP buffer. The RNA and DNA were quantified
using UV spectrophotometer by measuring their absorbance at 260nm. The protein was quan-
tified using BCA protein assay kit (Thermo scientific, Rockford, IL). However, the quantity of
protein from the some samples, especially HIV positive smokers and HIV positive nonsmok-
ers, were very low and insufficient for complete analysis.
Quantitative reverse transcriptase polymerase chain reaction (RTPCR)
Quantitative RTPCR was performed as described in our previous studies [18]. Briefly, 60 ng of
RNA was reverse transcribed to cDNA and then amplified in an iCycler iQ system (Bio-Rad
Laboratories, Hercules, CA) using a two-step TaqMan Gene Expression Kit (Applied Biosys-
tems, Foster City, CA). We measured the gene expression levels of following CYPs and AOEs:
CYP2A6 (Hs0071162 _ m1), CYP2E1 (Hs00559367_m1), CYP3A4 (HS00430021_m1), Cata-
lase (Hs00156308 m1), SOD1 (Hs00533490 m1), and Nrf2 (Hs00232352_m1) by using the
probes obtained from Applied biosystems. The relative fold expression was calculated using
2-ΔΔCt method by employing glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the
housekeeping gene.
Statistical analysis
Demographic variables (age, sex ratio) were summarized using descriptive statistics. All out-
come variables were summarized as the mean plus or minus the standard error. Comparisons
among the four groups were conducted using one way ANOVA with no corrections for multi-
ple comparisons. All tests were two-sided and results that were statistically borderline signifi-
cant at p0.1 (#) and significant at p0.05 () and0.01 (). A two-way ANOVA was done
Viral Load and Oxidative Stress in HIV-Infected Smokers
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to determine whether they interact synergistically or additively in HIV positive smokers. All
analyses were performed using IBM SPSS version 21.
Results
Characteristics of the study population
A total of 32 subjects were selected upon screening approximately 2000 HIV positive individu-
als attending the HIV clinic at the Regional Hospital, Mezam Polyclinic HIV/AIDS Treatment
Center, or at surrounding village health centers. The recruitment was very difficult and time
consuming owing to strict exclusion criteria, paucity of smokers who also do not also drink al-
cohol and are not yet receiving ART or other medications. Furthermore, smoking was rare
among women in this region, especially in HIV positive population in which it is discouraged.
The subjects with such inclusion criteria are nearly impossible to recruit in the USA, because
HIV-infected individuals receive ART promptly after diagnosis and most receive other medica-
tions and/or abuse illegal drugs. The recruitment of subjects who were not receiving ART was
critical to determine the specific effects of mild-to-moderate smoking in HIV-infected individ-
uals without an interference by drugs on the results of the study. The number of individuals in
each group (HIV negative non-smoker, HIV negative smoker, HIV positive non-smoker, and
HIV positive smoker) along with the age-range, median age, and male/female ratio of all the
subjects are presented in Table 1. The median age of all the groups was 35–45. The male/female
ratio varied in each group, with relatively low ratio in HIV positive group but high ratio in all
smokers because of the low incidence of smoking among women with the strict exclusion crite-
ria. Our analysis showed that the subject-to-subject variation in CD4 counts, viral load, cyto-
kine production, and oxidative stress was not significant on the basis of age and gender
differences (data not shown). This analysis was performed using HIV negative non-smokers
and HIV negative smokers, in which, the number of subjects were sufficient to perform
such analysis.
Effect of smoking and HIV on CD4 and viral load in plasma
The mean CD4 count (cells/μL) and mean viral load (log copies/mL) of each cohort are pre-
sented in Table 1 and Fig 1. As expected, the CD4 count was lower in HIV positive non-smok-
ers (374 ± 43) and HIV positive smokers (387 ± 130) than HIV negative non-smokers
(865 ± 45) or smokers (1037 ± 100). There was a significant increase in the CD4 count in HIV
negative smokers compared with non-smokers (1037 ± 100 vs. 865 ± 45). Our results showed
that the viral load is significantly increased in HIV positive smokers (4.5 ± 0.7) compared to
the HIV positive non-smokers (3.1 ± 0.5) (Fig 1A). These results suggest that smoking is asso-
ciated with increased viral replication.
Table 1. Demography and clinical outcomes (CD4) of the subjects.
Subjects HIV negative non-
smokers
HIV positive non-
smoker
HIV negative
smokers
HIV positive
smokers
Number, age (years), male/female
ratio
# 11 6 11 4
Age range 20–64 23–42 31–60 38–57
Median age 45 34.5 45.5 42
Male/
female
1.2 0.5 1.75 3
CD4 count (cells/μL) Range 631–1086 256–551 500–1488 13–584
Mean ± SE 865 ± 45 374 ± 43 1037 ± 100 387 ± 130
doi:10.1371/journal.pone.0122402.t001
Viral Load and Oxidative Stress in HIV-Infected Smokers
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Effect of CSC on HIV replication in primary macrophages
To further confirm the increase in viral load in HIV-infected smokers compared with HIV-in-
fected non-smokers, we treated HIV-infected primary macrophages with CSC for four days
(once-daily). CSC constitutes the majority of the cigarette constituents and is an accepted in
vitro substitute of smoking. The results showed that the amount of p24 antigen in cell free su-
pernatant was found to be significantly higher in CSC treated HIV-infected macrophages com-
pared to DMSO treated HIV-infected macrophages (Fig 1B).
Effect of smoking and HIV on cytokine/chemokine production in plasma
We determined the levels of various pro-inflammatory cytokines, IL-1β, IL-6, IL-8, RANTES,
TNF-α and MCP-1 in all plasma samples. The levels of IL-1β were not detectable in any plasma
sample within the detection limit of the assay (2 pg/mL). The concentrations of cytokines in each
group showed significant subject-to-subject variations, and therefore, we presented these results
in box plot as shown in Fig 2. The concentrations of most of the cytokines were in the range of
10–80 pg/mL, while the concentration of RANTES ranged from 500–12,000 pg/mL. The concen-
trations of MCP-1 and IL-8 were significantly lower in HIV positive non-smokers and HIV
Fig 1. Determination of viral loads in HIV-infected subjects (A) and HIV-infectedmacrophages (B). The
viral loads in the plasma of human subjects and macrophages were determined by analyzing HIV RNA using
q-RTPCR and p24 using ELISA, respectively. The data for in vitro assay (B) represents mean of multiple
analysis of p24 titer obtained from HIV-infected macrophages from three different donors. The p values
(# and ** represent p0.1 and p0.01, respectively) are calculated using one way-ANOVA and presented in
the graph.
doi:10.1371/journal.pone.0122402.g001
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negative smokers and marginally lower in HIV positive smokers than HIV negative non-smokers
(Fig 2). The concentration of RANTES was marginally higher in HIV positive non-smokers and
smokers than HIV negative non-smokers and smokers. However, there were no significant dif-
ferences in the levels of IL-6 and TNF-α between the test and control groups (Fig 2).
Effect of smoking and HIV on oxidative stress in plasma and monocytes
To evaluate oxidative stress in clinical samples, we determined the oxidative DNA damage by
measuring 8-OHdG content. The results showed that the oxidative damage is significantly
increased in plasma from HIV negative smokers (2-fold), and HIV positive non-smokers
(2.5-fold) groups compared with HIV negative non-smokers (Fig 3). Furthermore, there was
an additive increase in the levels of oxidative damage in HIV positive smokers (4-fold) com-
pared to HIV positive non-smokers and HIV negative smokers (two-way ANOVA for testing
the interaction gave p = 0.39 suggesting the absence of synergy). Similarly, we determined the
oxidative DNA damage in the monocytes of all the cohorts. Our results demonstrated an in-
crease in 8-OHdG levels in HIV negative smokers (~30%) and HIV positive non-smokers
(~40%) compared to HIV negative non-smokers (Fig 3). An additive increase was also ob-
served in 8-OHdG levels in the DNA of HIV positive smokers (~75%) compared to HIV posi-
tive non-smokers and HIV negative smokers. Overall, the results suggest an increase in
oxidative stress as a result of HIV infection and smoking.
Effect of smoking and HIV on the expression of antioxidants in
monocytes
The expression of antioxidant enzymes (AOEs) are generally induced to combat increased oxi-
dative stress triggered by an agent. Therefore we measured the levels of antioxidant genes;
SOD1, SOD2, catalase, and Nrf2 in our four cohorts. Our results demonstrated that the levels
Fig 2. Box and whisker plots of cytokine/chemokine levels in plasma of HIV negative non-smokers
(HEALTHY), HIV positive non-smokers (HIV), HIV negative smokers (SMOKER), and HIV positive
smokers (HIV SMOKER) groups. The box represents the 25th-75th quartile, the whiskers represent the
range of values, the median is presented as a line inside the box, and the out of range values are presented
as circles or stars above and below the whiskers. The p values (* and ** represent p0.05 and p0.01,
respectively) are calculated using one way-ANOVA and presented above the bars in the graph. The
concentrations of RANTES, IL-6, IL-8, MCP-1 and TNF-αwere shown in the figure.
doi:10.1371/journal.pone.0122402.g002
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of mRNA of the most antioxidant genes are not altered in HIV positive and/or smoker groups
compared to HIV negative non-smokers (Fig 4). However, we found a 2-fold increase in the
level of Nrf2 in HIV negative smokers compared to the HIV negative non-smoker. In general,
a lack of induction of the most AOEs suggest their inability to counterbalance oxidative stress
generated by smoking and HIV infection.
Effect of smoking and HIV on the levels of CYP enzymes in monocytes
CYP enzymes play important role in generating oxidative stress by generating superoxide and
peroxide as a result of P450-mediated reaction cycle. Therefore, we measured the levels of im-
portant CYP enzymes (CYP2A6, CYP2E1, and CYP3A4), which are known to produce oxida-
tive stress by metabolizing endogenous compounds or xenobiotics such as tobacco constituents
and marketed drugs. As expected, the results showed that the levels of CYP2A6 mRNA is in-
creased (p = 0.07; borderline significance) in HIV negative smokers (1.5-fold) compared to
HIV negative non-smokers (Fig 5). However, the level of CYP2A6 mRNA was only marginally
increased in HIV positive non-smokers and HIV positive smokers compared to HIV negative
non-smokers. Interestingly, the level of CYP3A4 was increased in HIV positive non-smokers
and HIV positive smokers by approximately 5-fold compared to HIV negative non-smokers
Fig 3. Measurement of oxidative stress in plasma andmonocyte samples of HIV negative non-
smokers (HEALTHY), HIV positive non-smokers (HIV), HIV negative smokers (SMOKER), and HIV
positive smokers (HIV SMOKER) groups. The 8-OHdG contents are plotted as a bar graph for each
category, and the p values0.05 and0.01 are represented as * and **, respectively. * represents the
significance with respect to HEALTHY, # represents the significance with respect to HIV and@ represents
the significance with respect to SMOKER in HIV SMOKER group.
doi:10.1371/journal.pone.0122402.g003
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Fig 4. Determination of antioxidant gene expression in HIV negative non-smokers (HEALTHY), HIV
positive non-smokers (HIV), HIV negative smokers (SMOKER), and HIV positive smokers (HIV
SMOKER) groups. The mRNA expressions of SOD1, SOD2, catalase, and Nrf2 were measured by
qRTPCR. A one way-ANOVA was employed to calculate the p value (* represent p0.05) with respect to
HEALTHY in all the groups.
doi:10.1371/journal.pone.0122402.g004
Fig 5. Determination of CYP levels in HIV negative non-smokers (HEALTHY), HIV positive non-
smokers (HIV), HIV negative smokers (SMOKER), and HIV positive smokers (HIV SMOKER) groups.
The expression levels of CYP2A6, CYP3A4, and CYP2E1mRNAwere determined by qRTPCR in all the
groups. A one way-ANOVA was employed to calculate the p value (** represent p0.01; # represents
p0.1, borderline significance) with respect to HEALTHY in all the groups.
doi:10.1371/journal.pone.0122402.g005
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(Fig 5). However, its level was not significantly increased in the HIV negative smokers. As ex-
pected, there was no significant increase in the level of CYP2E1 in HIV positive and/or smoker
cohorts, suggesting that CYP2E1, which is induced by alcohol, does not play role in inducing
oxidative stress in these cohorts.
Discussion
Nicotine/tobacco smoking has shown to increase HIV replication in in vitro studies [2,4]. In
vitro studies have also shown an association between oxidative stress and HIV replication
[9,10,13]. However, there is no clear evidence from the clinical samples of HIV-infected smok-
ers, especially in ART-naïve patients. Similarly, to date, there is no clinical evidence of the in-
volvement of CYP and oxidative stress pathways in HIV and/or smoking in HIV-infected
individuals. We have recently shown the involvement of CYP enzymes in nicotine metabolism
and oxidative stress in in vitro in HIV monocyte and astrocyte model systems. In the current
study, we used clinical samples from HIV-infected smokers to establish possible involvement
of CYP and oxidative stress pathways in smoking-mediated HIV pathogenesis. This is the first
clinical evidence of an increase in viral load in HIV-infected smokers, as well as, possible in-
volvement of CYP and oxidative stress pathways in HIV positive smokers and non-smokers. In
addition, in HIV-infected mature macrophages, HIV replication was found to be significantly
higher in CSC treated macrophages compared to control cells further supporting the effects of
smoking on HIV pathogenesis.
Several studies have shown that mild-to-moderate smoking leads to increased CD4 cell
count and CD4/CD8 ratio [35]. In contrast, another study reported that heavy smoking caused
a decline in CD4 cell count [36]. Our findings are generally consistent with the former literature
in which smoking showed an increase in the CD4 counts. Our study also suggest an increase in
HIV replication by tobacco smoking, which is consistent with previous in vitro findings [2,3].
However, this is the first report on clinical samples obtained from HIV-infected smokers. An
earlier study in HIV-seropositive women has shown an association of cigarette smoking with
viral immune and cognitive function [37]. However, the underlying mechanism of the effects of
smoking on viral immune, cognitive function, and HIV pathogenesis is largely unknown.
HIV infection is known to increase the expression of pro-inflammatory cytokines including
IL-1, IL-6, RANTES, MCP-1 and TNF-α [38,39]. In contrast, our results did not show an in-
crease in the levels of these cytokines in HIV positive cohorts, rather there were significant de-
crease in the levels of IL-8 and MCP-1. There is a report demonstrating that the levels of TNF-
α, IL-1β and IL-8 are significantly higher in asymptomatic HIV-infected African women than
women living with AIDS, suggesting the role of cytokines in early phase of HIV infection [40].
Thus, it is likely that unaltered/decrease in cytokines levels in our study is because the HIV-in-
fected patients had in many cases already progressed to full-blown AIDS. Likewise, cigarette
smoking is associated with an increased production of pro-inflammatory cytokines, especially
IL-1β and IL-1RA in bronchoalveolar lavage [41], and IL-6, IL-1β and TNF-α in the serum
[42,43]. In contrast, in our study, smoking was not associated with an increase in the levels
of pro-inflammatory cytokines, except RANTES, rather it showed a decrease in the levels of
IL-8 and MCP-1.
Tobacco smoking has been shown to affect cytokine network balance and there by alter the
host immune responses in the pathogenesis of both periodontal disease and cardiovascular
disease. For instance, both nicotine and cigarette smoke condensate treatment to human endo-
thelial cells had significantly reduced MCP-1 levels in those cells compared to control [44].
Similarly, a study conducted in smokers with computed tomography (CT) detected emphyse-
ma and without airway obstruction had demonstrated decreased plasma levels of cytokines
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including EGF, IL-8, IL-15, and IL-1RA than the smokers without CT detected emphysema
[45]. In contrast, patients with COPD usually exhibit higher IL-8 levels. Therefore these studies
suggests that the plasma cytokine profiles of smokers widely vary in individuals with either em-
physema or COPD. This also suggests that smoking could differentially affect the cytokine lev-
els based on their respiratory disease conditions which may be responsible for the decreased
levels of cytokines observed in our smokers and HIV positive smokers. Moreover, it is well
known that HIV-1 infection alters the levels of cytokine production in vitro as well as in vivo
[46]. Nonetheless, there is no report till date about correlation between smoking associated in-
creased viral load and cytokine levels. Therefore an extensive longitudinal study that monitors
the clinical status of smokers can provide us with a better understanding of the relation be-
tween smoking prompted viral load and their cytokine profiles. In general, we acknowledge
that our data show contrasting findings, which needs to be investigated further. However, it
can be noted that the population demography in our study is different from other studies in
terms of strict exclusion criteria of the subjects (non-HIV medication as well as use of other
substances of abuse).
An increase in the oxidative stress in both plasma and monocytes in smokers and HIV-
infected individuals is consistent with the previous reports, especially with monocytes
[9,10,13,47]. However, this is the first evidence of increased oxidative DNA damage in the plas-
ma and monocytes using clinical samples from HIV-infected smokers. It is noteworthy that
while a previous report has shown higher serum 8-OHdG levels in males versus females [48],
no gender difference in 8-OHdG level was observed in our study, at least in HIV negative non-
smokers and HIV positive smokers. Further, a relatively higher levels of oxidative DNA dam-
age in plasma compared with monocyte samples in all the groups suggests that there may be
increased oxidative stress in other tissues draining into plasma. While the DNA damage in
plasma may be as a result of ROS generated by liver and other blood cells including monocytes,
DNA damage in monocytes is expected to entirely come from increased ROS in monocytes.
An optimal level of ROS is required for cellular functions. However, when the level of ROS
is elevated, defense mechanism may counterbalance the increased ROS to protect the cells. As
one of the major defense mechanism, the Nrf2 signaling pathway is activated, which results in
the transcription of a myriad of AOEs such as SOD1 and catalase to protect the cells from oxi-
dative insult [49]. However, if the ROS reaches a threshold level, the AOEs pathway is compro-
mised leading to cellular death. On the other hand, a defect in the defense system may cause
either a decrease or no change in the levels of these AOEs leading to increased level of ROS.
Since there is no significant increase in the levels of AOEs determined in smokers, we suggest
that the levels of ROS has reached the threshold level, or the defense system through the Nrf2
pathway may be compromised in these individuals.
The role of oxidative stress as a result of production of ROS, including nitric oxides has been
implicated in HIV pathogenesis [9–11,50,51]. Similarly, previous literature [2–4,16,18,19] and
our current findings demonstrate that smoking and oxidative stress both are independently as-
sociated with increased HIV replication. Thus, we suggest that smoking-mediated oxidative
stress may be responsible for increased HIV replication. Although several mechanisms have
been implicated in the production of oxidative stress in the HIV systems, smoking mediated
production of ROS through CYP pathway may play an important role in HIV pathogenesis.
Since CYP-mediated metabolism of tobacco constituents is known to produce reactive oxygen
species in the liver [52], it is reasonable to conclude that CYP-mediated pathways contributes to
the DNA damage in both plasma and monocytes. Our results relatively low levels of DNA dam-
age in monocytes suggest that CYP-mediated metabolic pathway also exists in monocytes. Our
speculation is consistent with our earlier observation that although monocytes contain relatively
low levels of CYP enzymes compared to the liver, the relative level of CYP2A6 in monocytes is
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much higher that other CYP enzymes [24]. Therefore, we suggest that although CYP2A6 in
smokers and HIV positive non-smokers are not induced, the basal level of CYP2A6 is sufficient
to metabolize tobacco constituents and endogenous compounds and produce ROS. Further-
more, our observation is consistent with the recent finding that CYP2A6 mediated metabolism
of nicotine produces ROS in monocytes and astrocytes [18,19], which may be responsible for in-
creased DNA damage in monocytes. Another recent study from our laboratory, which demon-
strated an increased metabolism of nicotine in HIV positive smokers compared to HIV negative
smokers, is also consistent with this observation [53]. It is also possible that the increased metab-
olism is due to increased activity of enzyme rather than the actual protein level. An increase in
enzyme activity through substrate-mediated enhance stability of enzyme is known in the P450
system [54].
The CYP pathway is also known to produce oxidative stress through the metabolism of en-
dogenous compounds and xenobiotics such as marketed drugs [55]. The major drug-metabo-
lizing enzyme CYP3A4, which is also known to metabolize many endogenous compounds and
is present at relatively much higher level than other CYP enzymes in the liver, is expected to
produce oxidative stress. A significant increase in the level of CYP3A4 in HIV-infected non-
smokers as well as in HIV-infected smokers suggest an important role of CYP3A4 in HIV path-
ogenesis. It is possible that induction of CYP3A4 by HIV pathogenesis increases the metabo-
lism of many endogenous compounds as well as xenobiotics, which in turn leads to increased
oxidative stress. Since oxidative stress is also linked with HIV replication, the induction of
CYP3A4 would further increase HIV replication. In addition to its role in oxidative stress,
CYP3A4 may play significant role in HIV patients who are receiving ART, especially non-nu-
cleoside reverse transcriptase inhibitor (NNRTIs), protease inhibitors (PIs), and more recently
integrase inhibitors. CYP3A4 metabolizes majority of NNRTIs, integrase inhibitors, and all the
PIs, which are an essential component of ART [23]. Thus, increased level of CYP3A4 in HIV
positive smokers and HIV positive non-smokers would increase the metabolism of NNRTIs,
PIs, and integrase inhibitors in these individuals. An increased metabolism of ART would sub-
sequently decrease the bioavailability of these ARTs ultimately leading to decreased response
to these drugs and increased toxicity. Therefore, further investigation to clarify the role of
CYP3A4 in HIV-infected individuals over time is necessary.
In conclusion, the current study suggests that mild-to-moderate smoking increases viral
load in HIV-infected individuals, which was further confirmed using in vitro increased viral
replication by CSC in HIV-infected macrophages. Furthermore, our study suggests that smok-
ing and HIV independently increase oxidative stress in the plasma as well as in monocytes. An
increase in oxidative stress could be as a result of both, CYP-mediated hepatic metabolism of
smoking constituents and/or endogenous compounds and lack of induction of AOEs. Al-
though we suggest a possible association of CYP and oxidative stress pathways in HIV replica-
tion, other pathways cannot be excluded. Therefore, there is a need to further investigate CYP
or alternative pathways in smoking mediated HIV pathogenesis using in vitro HIV-infected
macrophages as well as in an in vivo HIV-infected humanized mice model.
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